Alzheimer’s Disease research is advancing with developments like Roche’s new biomarker blood test. Yet 98% of AD clinical ...

Under the partnership, Lilly will pay IU up to $40 million to build clinical trial infrastructure, accelerate access to neurology care and train IU students.

Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...

Eli Lilly and Co. and Indiana University on Wednesday announced a new agreement that would see the Indianapolis-based ...

INDIANAPOLIS — Indiana University and pharmaceutical giant Eli Lilly have made official a five-year collaboration in which ...

Indiana University and Eli Lilly are working together to expand clinical trials in the state. IU President Pamela Whitten and Lilly CEO David Ricks signed a $40 million, five-year deal Wednesday.

Eli Lilly and Indiana University partner to expand clinical trials and innovative treatments for Hoosiers, focusing initially on Alzheimer's disease.

Indiana University and Eli Lilly and Company have signed a five-year agreement that will provide up to $40 million to expand access to clinical trials, ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...